Back to discover
Disease
Antisynthetase syndrome
Late-stage therapeutic development
Also known as AS syndrome, anti-Jo1 syndrome.
7
Clinical trials
1
Associated genes
1
Related proteins
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Clinical trial2026-07-24Status changed to Completed · ClinicalTrials.gov
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 2 clinical trials expected to report results, the earliest in Q3 2027.
Upcoming Milestones
- Q3 2027A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome
- Q4 2027A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase Syndrome
Major developments
Upcoming trial readoutImportant
Results expected Q4 20272026-04-23
Upcoming trial readoutImportant
Results expected Q3 20272026-06-03
Clinical MilestonesViewHide
Results expected
- 2026-06-03A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase SyndromeResults expected Q3 2027
- 2026-04-23A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase SyndromeResults expected Q4 2027
Recently completed
- 2026-07-02A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory MyopathyCompleted
- 2025-10-20An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid ArthritisPrimary completion
- 2025-09-25Treatment With add-on IVIg in Myositis Early In the diSease Course May be sUperior to Steroids Alone for Reaching CLinical improvemEntPrimary completion
Activity timeline5
- 2026-07-02ClinicalA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory MyopathyCompleted
- 2026-06-03ClinicalA Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase SyndromeResults expected Q3 2027
- 2026-04-23ClinicalA Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase SyndromeResults expected Q4 2027
- 2025-10-20ClinicalAn Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid ArthritisPrimary completion
- 2025-09-25ClinicalTreatment With add-on IVIg in Myositis Early In the diSease Course May be sUperior to Steroids Alone for Reaching CLinical improvemEntPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
7
4
2
1
Late-stage studies
Recruiting
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
AS syndrome, anti-Jo1 syndrome
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.